Passiniemi; Mikko
Patent Applications and Registrations
Patent applications and USPTO patent grants for Passiniemi; Mikko.The latest application filed is for "pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors".
- Passiniemi; Mikko - Helsinki FI
| Patent | Date |
|---|---|
| Pyran Dervatives As Cyp11a1 (cytochrome P450 Monooxygenase 11a1) Inhibitors App 20210347765 - DIN BELLE; David ; et al. | 2021-11-11 |
| Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors Grant 11,098,032 - Din Belle , et al. August 24, 2 | 2021-08-24 |
| Pyran Dervatives As Cyp11a1 (cytochrome P450 Monooxygenase 11a1) Inhibitors App 20200299280 - DIN BELLE; David ; et al. | 2020-09-24 |
| Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors Grant 10,717,726 - Din Belle , et al. | 2020-07-21 |
| Pyran Dervatives As Cyp11a1 (cytochrome P450 Monooxygenase 11a1) Inhibitors App 20190359601 - DIN BELLE; David ; et al. | 2019-11-28 |
| CYP17 inhibitors/antiandrogens Grant 9,890,139 - Wohlfahrt , et al. February 13, 2 | 2018-02-13 |
| Novel Cyp17 Inhibitors/antiandrogens App 20160130254 - WOHLFAHRT; Gerd ; et al. | 2016-05-12 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 